A newly highlighted gut bacterium is sparking a massive pharma land grab. But who is truly profiting from this 'good health' discovery?
Forget insulin resistance. The latest research points to an immune system target for Type 2 Diabetes, signaling a seismic shift in metabolic treatment.
Madrigal's massive siRNA licensing deal signals a dangerous consolidation in the MASH drug race. The real winner isn't the patient.
Forget the headlines. The real drivers of skyrocketing US healthcare costs aren't just Big Pharma—they're the silent epidemics fueled by nutritional ignorance, a topic journalists are finally dissecting.
Employers pushing for metabolic health benefits aren't just chasing wellness; they are strategically optimizing their workforce while subtly shifting risk. Unpacking the real agenda.
GLP-1s are bankrupting health insurers faster than predicted. This isn't just about weight loss; it's a systemic failure.